Autodesk Inc vs Neurocrine Biosciences Inc — how do they compare? Autodesk Inc trades at $249 (market cap $53.12B), while Neurocrine Biosciences Inc trades at $151.75 (market cap $16.46B). The key difference: Autodesk Inc is far larger — about 3.2× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.
| ADSK | NBIX | |
|---|---|---|
Market Cap | $53.12B | $16.46B |
Sector | Technology | Health |
52-Week High | $326.79 | $185.50 |
52-Week Low | $187.72 | $123.10 |
Enterprise Value | $52.92B | $16.48B |
Trailing returns across standard periods
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →